Cancer management during the COVID-19 world pandemic
Cancer Immunology, Immunotherapy · 2023
DOI: 10.1007/s00262-023-03524-1 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Immunology, Immunotherapy, 2023. Verfasst von Navid Sobhani und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Section of Epidemiology and Population Sciences, Baylor College of Medicine, Houston, TX, 77030, USA. NSobhani@mdanderson.org. Hauptthemen laut MEDLINE: COVID-19, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: MEDnoTE srl.
Abstract (Originalsprache)
Since 2019, the world has been experiencing an outbreak of a novel beta-coronavirus, severe acute respiratory syndrome coronavirus (SARS-CoV)-2. The worldwide spread of this virus has been a severe challenge for public health, and the World Health Organization declared the outbreak a public health emergency of international concern. As of June 8, 2023, the virus' rapid spread had caused over 767 million infections and more than 6.94 million deaths worldwide. Unlike previous SARS-CoV-1 and Middle East respiratory syndrome coronavirus outbreaks, the COVID-19 outbreak has led to a high death rate in infected patients; this has been caused by multiorgan failure, which might be due to the widespread presence of angiotensin-converting enzyme 2 (ACE2) receptors-functional receptors of SARS-CoV-2-in multiple organs. Patients with cancer may be particularly susceptible to COVID-19 because cancer treatments (e.g., chemotherapy, immunotherapy) suppress the immune system. Thus, patients with cancer and COVID-19 may have a poor prognosis. Knowing how to manage the treatment of patients with cancer who may be infected with SARS-CoV-2 is essential. Treatment decisions must be made on a case-by-case basis, and patient stratification is necessary during COVID-19 outbreaks. Here, we review the management of COVID-19 in patients with cancer and focus on the measures that should be adopted for these patients on the basis of the organs or tissues affected by cancer and by the tumor stage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Section of Epidemiology and Population Sciences, Baylor College of Medicine, Houston, TX, 77030, USA. NSobhani@mdanderson.org.
- Royal Infirmary Hospital, Foresterhill Health Campus, Foresterhill Rd, Aberdeen, AB25 2ZN, UK.
- Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy.
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy.
- Department of Biology and Biochemistry, University of Bath, Bath, BA2 7AX, UK.
- Department of Life Sciences, University of Trieste, 34127, Trieste, Italy.
Förderung
- MEDnoTE srl
Zitieren
APA
Sobhani, N., Mondani, G., Roviello, G., Catalano, M., Sirico, M., D'Angelo, A., Scaggiante, B., & Generali, D. (2023). Cancer management during the COVID-19 world pandemic. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-023-03524-1
Vancouver
Sobhani N, Mondani G, Roviello G, Catalano M, Sirico M, D'Angelo A, et al. Cancer management during the COVID-19 world pandemic. Cancer Immunology, Immunotherapy. 2023. doi:10.1007/s00262-023-03524-1
BibTeX
@article{Sobhani2023,
author = {Sobhani, Navid and Mondani, Giuseppina and Roviello, Giandomenico and Catalano, Martina and Sirico, Marianna and D'Angelo, Alberto and Scaggiante, Bruna and Generali, Daniele},
title = {Cancer management during the COVID-19 world pandemic},
journal = {Cancer Immunology, Immunotherapy},
year = {2023},
doi = {10.1007/s00262-023-03524-1}
}
EUVIMED